We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In comments to the FDA, drugmakers called on the agency to clarify in its draft guidance for biosimilar and interchangeable insulin products that the agency will still hold applicants to the current licensing standards. Read More
The White House supports a bipartisan bill, S. 2543, that would impose fines on pharma companies that hike Medicaid drug prices high above the inflation rate. Read More
The Department of Justice plans to continue its investigation into anticompetitive activity in the generic drug industry, according to a senior DOJ official. Read More
The Trump administration’s fiscal 2021 budget proposal unveiled Monday seeks an increase of 4.5 percent for the FDA while cutting most other non-defense spending. Read More
California’s State Board of Pharmacy is considering a request to revoke or suspend McKesson’s wholesale permit for “excessively” supplying controlled substances to a children’s pharmacy that are not typically distributed to pediatric patients. Read More
The Department of Justice (DOJ) has indicted a former Taro Pharmaceuticals executive for allegedly conspiring to fix numerous generic drug prices. Read More
ICER will launch a pilot program for updating assessments after a medicine approved under the FDA’s accelerated approval pathway has been on the market for at least two years. Read More